Acorda therapeutics receives NIH Phase 2 grant for central nervous system repair
Hawthorne, NY December 19, 2002 Acorda Therapeutics announced today that it has been awarded a two-year Phase 2 Small Business Technology Transfer (STTR) grant from the National Institutes of Health. The $980,000 grant will continue to fund collaborative research between Acorda and Drs. Allan Bieber and Moses Rodriguez of Mayo Clinic. The grant will fund research at Acorda and at Mayo Clinic t...Acorda Therapeutics acquires CeNeS neuregulin products
Hawthorne, NY November 14, 2002 Acorda Therapeutics announced today that it has acquired an exclusive worldwide license from CeNeS plc (LSE: CEN) to its neuregulin products, glial growth factor 2 (GGF2), and neuregulin 2 (NRG2), a class of therapeutic agents that has been demonstrated to promote remyelination in animal studies. ...... Acorda expects to advance pre-clinical development immediatel...Acorda Therapeutics receives L.W. Freeman Award for Scientific Research
Hawthorne, NY /Mesa, AZ November 13, 2002 - Acorda Therapeutics, a biotechnology company located in Hawthorne, NY, will receive the L.W. Freeman Award for Scientific Research tomorrow evening at the National Spinal Cord Injury Association (NSCIA) 2002 Annual Conference in Mesa, AZ. ...... This award is given annually for pioneering research on regeneration in spinal cord injury or disease and was...Acorda Therapeutics begins Phase 3 trials of Fampridine-SR for chronic spinal cord injury
Hawthorne, NY June 28, 2002 Acorda Therapeutics announced today that it has begun two Phase 3 clinical studies of its lead product, Fampridine-SR, in chronic spinal cord injury. The trials will evaluate the safety and efficacy of Fampridine-SR in the treatment of moderate-to-severe spasticity associated with chronic SCI. Spasticity, which affects up to 75% of people with chronic SCI, manifests...